Skip to main content
CRDF logo

CRDF

Cardiff Oncology, Inc.

$1.27

3.41%

Trade Ideas Performance

Latest Closed Trade Idea

$1.27

3.41%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

18

Social

5

About

Events of Cardiff Oncology, Inc. (CRDF)

Over the past six months, Cardiff Oncology's stock price has experienced a decline. Positive Phase 2 CRDF-004 trial updates were reported in January 2026. Leadership changes occurred with CEO and CFO departures in January 2026, followed by key leadership appointments in April 2026. The company reported its Q4 2025 and Q3 2025 earnings. Clinical data from an investigator-sponsored Phase 1 trial evaluating onvansertib monotherapy in CMML were presented at ASH 2025. Preclinical data on onvansertib were presented at the AACR Annual Meeting 2026. An inducement equity grant was reported in April 2026.

Read more

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Cardiff Oncology, Inc. (CRDF) Live Stock Price, Chart & Financial News | Edge Hound